Press Releases
Press Releases
Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
The meeting will be held at the San Diego Convention Center and the scheduled times (noted in local Pacific Time) for the Allergan presentations, titles and authors are as follows: Podium PresentationsOnce-Daily Oral Sarecycline 1.5 mg/kg/day...
Press Releases
Amgen sets up a FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO
Amgen announced that the Oncologic Drugs Advisory Committee of the U.S. FDA will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia...
Press Releases
AbbVie presents New, Late Breaking Investigational Data at 2018 at AAD Annual meeting
AbbVie a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA® (adalimumab) at the 2018 American Academy of Dermatology (AAD) Annual Meeting (February 16-20, San Diego). ...
Press Releases
GSK’S Fluarix Tetra (Influenza Vaccine) for ages six months and older RECEIVES European Approval
GSK announced the expanded indication for Fluarix Tetra (Quadrivalent Influenza Vaccine) has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two influenza A...
Press Releases
GSK submits landmark IMPACT data to European Medicines Agencies for supporting Trelegy Ellipta
GlaxoSmithKline plc and Innoviva, Inc. announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) in Europe for...
Press Releases
FDA Approves Symdeko
Vertex Pharmaceuticals Incorporated announced that the U.S. FDA approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation in the cystic...
Press Releases
FDA Approves Erleada
The U.S. FDA approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
